NOTCH3 Variants and Risk of Ischemic Stroke

Owen A. Ross1*, Alexandra I. Soto-Ortolaza2, Michael G. Heckman2, Christophe Verbeeck1, Daniel J. Serie2, Sruti Rayaprolu1, Stephen S. Rich3, Michael A. Nalls4, Andrew Singleton4, Rita Guerreiro4,5,6, Emma Kinsella4,7, Zbigniew K. Wszolek8, Thomas G. Brott8, Robert D. Brown Jr. 9, Bradford B. Worrall10, James F. Meschia8

1 Department of Neuroscience, Mayo Clinic, Jacksonville, Florida, United States of America, 2 Section of Biostatistics, Mayo Clinic, Jacksonville, Florida, United States of America, 3 Center for Public Health Genomics, University of Virginia, Charlottesville, Virginia, United States of America, 4 Laboratory of Neurogenetics, National Institute on Aging, National Institutes of Health, Bethesda, Maryland, United States of America, 5 Department of Molecular Neuroscience and Reta Lila Weston Laboratories, Institute of Neurology, London, United Kingdom, 6 Center for Neuroscience and Cell Biology, University of Coimbra, Coimbra, Portugal, 7 Cardiff University School of Medicine, Cardiff, United Kingdom, 8 Department of Neurology, Mayo Clinic College of Medicine, Jacksonville, Florida, United States of America, 9 Department of Neurology, Mayo Clinic, Rochester, Minnesota, United States of America, 10 Department of Neurology, University of Virginia, Charlottesville, Virginia, United States of America

Abstract

Background: Mutations within the NOTCH3 gene cause cerebral autosomal dominant arteriopathy with subcortical infarcts and leukoencephalopathy (CADASIL). CADASIL mutations appear to be restricted to the first twenty-four exons, resulting in the gain or loss of a cysteine amino acid. The role of other exonic NOTCH3 variation not involving cysteine residues and mutations in exons 25-33 in ischemic stroke remains unresolved.

Methods: All 33 exons of NOTCH3 were sequenced in 269 Caucasian probands from the Siblings With Ischemic Stroke Study (SWISS), a 70-center North American affected sibling pair study and 95 healthy Caucasian control subjects. Variants identified by sequencing in the SWISS probands were then tested for association with ischemic stroke using US Caucasian controls collected at the Mayo Clinic (n=654), and further assessed in a Caucasian (n=802) and African American (n=298) patient-control series collected through the Ischemic Stroke Genetics Study (ISGS).

Results: Sequencing of the 269 SWISS probands identified one (0.4%) with small vessel type stroke carrying a known CADASIL mutation (p.R558C; Exon 11). Of the 19 common NOTCH3 variants identified, the only variant significantly associated with ischemic stroke after multiple testing adjustment was p.R1560P (rs78501403; Exon 25) in the combined SWISS and ISGS Caucasian series (Odds Ratio [OR] 0.50, P=0.0022) where presence of the minor allele was protective against ischemic stroke. Although only significant prior to adjustment for multiple testing, p.T101T (rs3815188; Exon 3) was associated with an increased risk of small-vessel stroke (OR: 1.56, P=0.008) and p.P380P (rs61749020; Exon 7) was associated with decreased risk of large-vessel stroke (OR: 0.35, P=0.047) in Caucasians. No significant associations were observed in the small African American series.

Conclusion: Cysteine-affecting NOTCH3 variations are rare in patients with typical ischemic stroke, however our observation that common NOTCH3 variants may be associated with risk of ischemic stroke warrants further study.

Citation: Ross OA, Soto-Ortolaza AI, Heckman MG, Verbeeck C, Serie DJ, et al. (2013) NOTCH3 Variants and Risk of Ischemic Stroke. PLoS ONE 8(9): e75035. doi:10.1371/journal.pone.0075035

Editor: Christian Wider, Centre Hospitalier Universitaire Vaudois (CHUV), Switzerland

Received April 27, 2013; Accepted August 8, 2013; Published September 23, 2013

This is an open-access article, free of all copyright, and may be freely reproduced, distributed, transmitted, modified, built upon, or otherwise used by anyone for any lawful purpose. The work is made available under the Creative Commons CC0 public domain dedication.

Funding: OAR is a recipient of a James and Ester King Foundation New Investigator Award from the Department of Health, Florida State. OAR is also funded by the American Heart Association (AHA) and the Myron and Jane Hanley Award in Stroke Research. The Siblings with Ischemic Stroke Study was funded by a grant from the National Institute of Neurological Disorders and Stroke (NINDS) (R01 NS39987; JFM, PI) and by a Marriott Disease Risk and Regenerative Medicine Initiative Award in Individualized Medicine. The Ischemic Stroke Genetics Study (ISGS) was funded by a grant from the NINDS (R01 NS42733). ZKW is supported in part by the National Institutes of Health (NIH) /NINDS P50 NS072187, Mayo Clinic Center for Regenerative Medicine, and Dystonia Medical Research Foundation. This work was supported in part by the Intramural Research Program of the National Institute on Aging, NIH, Department of Health and Human Services, project number Z01 AG000950-06; the UK Motor Neurone Disease Association grant 6057 to John Hardy and Richard Orrell and Alzheimer's Research UK funding to John Hardy. This work was supported in part by the Wellcome Trust/MRC Joint Call in Neurodegeneration award (WT089698) to the UK Parkinson's Disease Consortium (UKPDC) whose members are from the UCL/Institute of Neurology, the University of Sheffield and the MRC Protein Phosphorylation Unit at the University of Dundee and a fellowship from Alzheimer’s Research UK to Dr. Guerreiro. The funders had no role in study design, data collection and analysis, decision to publish, or preparation of the manuscript.

Competing interests: Owen A. Ross is a PLOS ONE Editorial Board member. This does not alter the authors’ adherence to all the PLOS ONE policies on sharing data and materials.

* E-mail: ross.owen@mayo.edu
inherited forms. The classical linkage method employing large age-at-death is estimated to be about 60 years [5].

Ischemic stroke is by far the phenotype correlation with CADASIL [4]. The clinical colleagues reported the identification of the first genetic locus 3 to 43 years [7]. There is no specific treatment for CADASIL familial aggregates that display Mendelian patterns of stroke same family [6]. The age-at-onset can range from 30-94 years, dominant arteriopathy with subcortical infarctions and for stroke, with pathogenic mutations in the [OMIM*600276] observed to cause CADASIL [3].

The disease course of CADASIL is variable, even in the brief, adult (>18 years old) probands were recruited at 70 US and Canadian medical centers with a study neurologist–confirmed ischemic stroke. Stroke was defined as rapidly death, with no apparent cause other than vascular origin (World Health Organization definition) [12]. Stroke was referred to as Octogenarian sporadic patient with a minor stroke demonstrating the potential role of NOTCH3 mutations with less severe presentation [8,9].

Introduction

One of the most successful approaches to the mapping of disease-related genes has been the identification of rare inherited forms. The classical linkage method employing large familial aggregates that display Mendelian patterns of stroke inheritance (dominant/recessive) has identified genes involved in monogenic forms of disease [1,2]. Cerebral autosomal-dominant arteriopathy with subcortical infarctions and leukoencephalopathy (CADASIL; OMIM #125310), is a rare form of small-vessel occlusive disease. In 1996, Joutel and colleagues reported the identification of the first genetic locus for stroke, with pathogenic mutations in the NOTCH3 gene [OMIM*600276] observed to cause CADASIL [3].

Over 50 NOTCH3 mutations have been reported, and to date there does not appear to be a consistent genotype-phenotype correlation with CADASIL [4]. The clinical phenotype of CADASIL usually presents with ischemic stroke or transient ischemic attack, cognitive deficits, migraine with aura, or psychiatric disturbance. Ischemic stroke is by far the most common manifestation, occurring in up to 85% of patients [5]. The disease course of CADASIL is variable, even in the same family [6]. The age-at-onset can range from 30-94 years, with early-onset forms not necessarily predicting a more severe symptomatic progression, and disease duration range between 3 to 43 years [7]. There is no specific treatment for CADASIL with most therapies focused on symptomatic control, the mean age-at-death is estimated to be about 60 years [5]. Interestingly, a NOTCH3 mutation was identified in an octogenarian sporadic patient with a minor stroke demonstrating the potential role of NOTCH3 mutations with less severe presentation [8,9]. Recently a novel mutation was reported p.L1515P, which is hypothesized to hyperactivate the NOTCH3 receptor, suggesting alternative mechanisms of pathogenicity [10]. However the actual pathomechanism behind NOTCH3 mutations that are characteristic of CADASIL and ischemic stroke remains unclear. NOTCH3 signaling has also been implicated in ischemic stroke and studies suggest that the NOTCH3 protein is a determinant of stroke burden via vascular smooth muscle cells [11].

Given the reduced penetrance and clinical heterogeneity, we hypothesized that NOTCH3 variants may play a greater role in ischemic stroke than previously thought. Herein, we present a complete exon screening of NOTCH3 in 269 Caucasian probands with familial ischemic stroke and follow-up the identified variants in an association approach with a Caucasian and African-American patient-control series.

Subjects and Methods

We utilized two different ischemic stroke patient-control series to investigate the role of NOTCH3 variation in ischemic stroke; patient characteristics for each series are displayed in Table 1. For comprehensive sequence analysis, we employed a series of 269 Caucasian US familial stroke patients collected through the Siblings With Ischemic Stroke Study (SWISS). In brief, adult (>18 years old) probands were recruited at 70 US and Canadian medical centers with a study neurologist–confirmed ischemic stroke. Stroke was defined as rapidly developing signs of a focal or global disturbance of cerebral function, with symptoms lasting at least 24 hours or leading to death, with no apparent cause other than vascular origin (World Health Organization definition) [12]. Stroke was referred
Table 2. NOTCH3 variants identified by Sequencing in SWISS probands and controls.

| Position | Exon | Genotype | SNP       | Amino Acid |
|----------|------|----------|-----------|------------|
| 15303225 | 3    | C>T      | rs3815188 | T101T      |
| 15302941 | 4    | A>g      | rs147373451 | H170R     |
| 15302844 | 4    | G>A      | rs1043994 | A202A      |
| 15302792 | 4    | C>T      | rs114457076 | Y220Y     |
| 15302328 | 6    | C>T      | rs156239440 | I315I     |
| 15301136 | 7    | T>C      | rs61749200 | P380P     |
| 15299051 | 9    | C>T      | rs11670979 | P496L     |
| 15299050 | 9    | C>T      | rs114207045 | S497L    |
| 15298806 | 10   | C>T      | rs142762020 | G498G     |
| 15298600 | 10   | C>T      | rs146055867 | S500S     |
| 15288084 | 11   | C>T      | rs75068032 | R558C     |
| 15286034 | 11   | G>A      | rs79926127 | T575T     |
| 15297974 | 11   | C>T      | rs35793556 | S594G     |
| 15296164 | 14   | C>T      | rs14004122 | A734A     |
| 15295134 | 16   | T>C      | rs1043996 | C484C     |
| 15292437 | 17   | G>A      | rs1043997 | P914P     |
| 15291625 | 18   | C>T      | rs14369196 | H981Y†    |
| 15291576 | 19   | G>C      | rs35769976 | A1020P    |
| 15291553 | 19   | G>T      | rs146829488 | W1028L    |
| 15290265 | 21   | C>T      | rs140642726 | D1124D    |
| 15290238 | 21   | C>A      | rs112197217 | H1133Q    |
| 15290007 | 22   | G>A      | rs10408676 | V1183M    |
| 15288695 | 24   | C>A      | rs78926093 | G1348G†    |
| 15285052 | 25   | G>A      | rs1044006 | P1521P     |
| 15284978 | 25   | C>G      | rs150037063 | L1547V     |
| 15284938 | 25   | G>C      | rs78501403 | R1560P     |
| 15281580 | 26   | A>T      | rs201187365 | D1598V†    |
| 15281344 | 27   | A>G      | rs149222385 | E1638E     |
| 15280969 | 28   | G>A      | rs143411026 | G1710D     |
| 15276739 | 30   | T>C      | rs16980398 | A1842A     |
| 15273337 | 32   | G>A      | rs115582213 | V1952M     |
| 15272410 | 33   | G>A      | rs142077575 | V2011†     |
| 15272343 | 33   | C>T      | rs145859816 | P2033L     |
| 15272218 | 33   | G>T      | rs11447350 | P2074L     |
| 15271999 | 33   | G>T      | rs141231747 | G2081V     |
| 15272001 | 33   | G>A      | rs1044008 | A2146A     |
| 15271771 | 33   | T>C      | rs1044009 | A2223V     |
| 15271684 | 33   | G>A      | rs61731975 | S2251S     |
| 15271628 | 33   | T>C      | rs61731974 | P2271P     |

† Chromosomal positions are based on the February 2009 (GRCH37/hg19) genome assembly. SNP=single nucleotide polymorphism. † Only observed in sequencing of 95 control subjects and not in subsequent screenings. na=not available.

doi: 10.1371/journal.pone.0075035.t002

To as ischemic when computed tomography or magnetic resonance imaging of the brain was performed within 7 days of onset of stroke symptoms and identified the symptomatic cerebral infarct or failed to identify an alternative cause of symptoms. Probands were required to have reported at least 1 living full sibling with a history of stroke. No proband was enrolled with iatrogenic vasospastic or vasculitic stroke or if the stroke occurred in the setting of a mechanical heart valve or in the setting of untreated or actively treated bacterial endocarditis. Probands were also excluded if they were known to have CADASIL, Fabry disease, homocysteinuria, MELAS, or sickle-cell anemia. Study neurologists at each center assigned to the qualifying ischemic stroke of each proband a Trial of Org 10172 in Acute Stroke Treatment (TOAST) subtype diagnosis [13]. In addition, 95 healthy controls were obtained from Coriell Cell Repositories (Camden, NJ) for sequencing. These samples originated from different regions of the world (USA, Israel, Uruguay, Poland, Greece, Ireland, Australia, United Kingdom, Germany, Wales, Netherlands, Canada, Colombia and Cuba) noted to have an absence of neurological conditions by sample submitters [14]. This cohort of 95 healthy controls had a mean age of 78 years (range 70 to 95 years) and included 46 females and 49 males.

For association and follow-up of variants, we supplemented the aforementioned 269 Caucasian familial stroke patients with a series of 654 Caucasian controls collected at the Mayo Clinic in Jacksonville, Florida, and we refer to this patient-control series as the familial Caucasian series. Additionally, we used a sporadic Caucasian patient-control series collected through the Ischemic Stroke Genetics Study (ISGS) which consisted of 452 stroke patients and 350 controls. Finally a small African American patient-control series collected as part of ISGS was studied, and this series was made of up 164 stroke patients and 131 controls. Subjects had age, gender, age at stroke, and type of stroke (cardioembolic, large vessel, small vessel, other, or undetermined) data collected. Additionally, information regarding atrial fibrillation, coronary artery disease, diabetes, hypertension, and current smoking was also collected in the two ISGS patient-control series’. We combined the familial Caucasian series and ISGS Caucasian series into a “combined Caucasian series” to be analyzed along with the individual series’.

Ethics Statement

The ethics committee and the institutional review board of the Mayo Clinic approved the study, and all participants provided written informed consent.

Genetic analysis

For all 33 NOTCH3 exons, bidirectional DNA sequencing was performed on an ABI 3730 DNA sequencer and analyzed using SeqScape v2.5 (Applied Biosystems). The variants were genotyped on a Sequenom MassArray iPLEX platform (San Diego, CA; primer sequences are available on request) and analyzed with Typer 4.0 software, an ABI on-demand Taqman assay (analyzed with SDS 2.2.2 software) or by direct exon sequencing on an ABI 3730. Assay Design software was used to multiplex the 34 variants identified during sequencing which were split into two iPLEX panels (primers available upon request). The rate of genotype calls was ≥95% in each series. Linkage disequilibrium (LD) measures were calculated and plotted using Haploview (Figure S1) [15].

Statistical analysis

For NOTCH3 variants occurring with a minor allele frequency of 1% or greater, associations with ischemic stroke were
Table 3. Summary of variants with a minor allele frequency of less than 1%.

| SNP          | Amino Acid | MAF     | Patients  | Controls | MAF     | Patients  | Controls | MAF     | Patients  | Controls |
|--------------|------------|---------|-----------|----------|---------|-----------|----------|---------|-----------|----------|
| rs147373451  | H170R      | 0.4%    | 1 (0.4%)  | 6 (0.9%) | 0.2%    | 2 (0.5%)  | 1 (0.3%) | 0.3%    | 3 (0.4%)  | 7 (0.7%) |
| rs114457076  | Y220Y      | 0.2%    | 2 (0.8%)  | 2 (0.3%) | <0.1%   | 1 (0.2%)  | 0 (0.0%) | 0.2%    | 3 (0.4%)  | 2 (0.2%) |
| rs116239440  | I515I      | 0.2%    | 2 (0.8%)  | 1 (0.2%) | 0.1%    | 2 (0.5%)  | 0 (0.0%) | 0.2%    | 4 (0.6%)  | 1 (0.1%) |
| rs11670799   | P436L      | T       | +         | +        | +       | +         | +        | +       | 0.2%      | (0.0%)   |
| rs114207045  | S497L      | 0.4%    | 3 (1.1%)  | 5 (0.8%) | 0.4%    | 4 (0.9%)  | 3 (0.9%) | 0.4%    | 7 (1.0%)  | 8 (0.8%) |
| rs142762020  | G496G      | <0.1%   | 1 (0.4%)  | 0 (0.0%) | 0.0%    | 0 (0.0%)  | 0 (0.0%) | <0.1%   | 1 (0.1%)  | 0 (0.0%) |
| rs146058676  | S500S      | 0.2%    | 1 (0.4%)  | 3 (0.5%) | 0.1%    | 2 (0.5%)  | 0 (0.0%) | 0.2%    | 3 (0.4%)  | 3 (0.3%) |
| rs75068032   | R586C      | <0.1%   | 1 (0.4%)  | 0 (0.0%) | 0.0%    | 0 (0.0%)  | 0 (0.0%) | <0.1%   | 1 (0.1%)  | 0 (0.0%) |
| rs79926127   | T575T      | 0.8%    | 6 (2.2%)  | 9 (1.4%) | 0.5%    | 7 (1.6%)  | 1 (0.3%) | 0.7%    | 13 (1.8%) | 10 (1.1%) |
| rs7593356    | G594G      | 0.2%    | 2 (0.7%)  | 2 (0.3%) | <0.1%   | 1 (0.2%)  | 0 (0.0%) | 0.2%    | 3 (0.4%)  | 2 (0.2%) |
| rs140040122  | A734A      | 0.2%    | 1 (0.4%)  | 3 (0.5%) | 0.1%    | 1 (0.2%)  | 1 (0.3%) | 0.2%    | 2 (0.3%)  | 4 (0.4%) |
| rs146829488  | W1028L     | <0.1%   | 1 (0.4%)  | 0 (0.0%) | 0.0%    | 0 (0.0%)  | 0 (0.0%) | <0.1%   | 1 (0.1%)  | 0 (0.0%) |
| rs140642726  | D1124D     | <0.1%   | 1 (0.4%)  | 0 (0.0%) | 0.0%    | 0 (0.0%)  | 0 (0.0%) | <0.1%   | 1 (0.1%)  | 0 (0.0%) |
| rs112197217  | H1133Q     | T       | +         | +        | +       | +         | +        | +       | 0.2%      | (0.6%)   |
| rs10408676   | V163M      | T       | +         | +        | 0.5%    | 3 (0.7%)  | 5 (1.4%) | +       | +         | +        |
| rs150037063  | L1547V     | 0.2%    | 1 (0.4%)  | 2 (0.3%) | 0.2%    | 1 (0.2%)  | 2 (0.6%) | 0.2%    | 2 (0.3%)  | 4 (0.4%) |
| rs149223385  | E1638E     | <0.1%   | 1 (0.4%)  | 0 (0.0%) | <0.1%   | 1 (0.2%)  | 0 (0.0%) | <0.1%   | 2 (0.3%)  | 0 (0.0%) |
| rs143411026  | G1710D     | <0.1%   | 1 (0.4%)  | 0 (0.0%) | <0.1%   | 1 (0.2%)  | 0 (0.0%) | <0.1%   | 2 (0.3%)  | 0 (0.0%) |
| rs16980398   | A1842A     | G       | +         | +        | 0.7%    | 5 (1.1%)  | 6 (1.7%) | +       | +         | +        |
| rs11582213   | V1952M     | T       | +         | +        | +       | +         | +        | +       | 0.0%      | (0.0%)   |
| rs145859816  | P2033L     | <0.1%   | 1 (0.4%)  | 0 (0.0%) | 0.0%    | 0 (0.0%)  | 0 (0.0%) | <0.1%   | 1 (0.1%)  | 0 (0.0%) |
| rs114447350  | P2074L     | 0.3%    | 2 (0.7%)  | 3 (0.5%) | 0.2%    | 2 (0.5%)  | 1 (0.4%) | 0.3%    | 4 (0.6%)  | 4 (0.5%) |
| rs141231747  | G2081V     | <0.1%   | 1 (0.4%)  | 0 (0.0%) | 0.0%    | 0 (0.0%)  | 0 (0.0%) | <0.1%   | 1 (0.1%)  | 0 (0.0%) |
| rs1044008    | A2146A     | T       | +         | +        | +       | +         | +        | +       | 0.5%      | 1 (0.6%) |
| rs6171975    | S2251S     | 0.4%    | 3 (1.1%)  | 4 (0.6%) | 0.2%    | 2 (0.5%)  | 1 (0.3%) | 0.3%    | 5 (0.7%)  | 5 (0.5%) |
| rs6171974    | P2271P     | G       | 0.2%     | 1 (0.4%) | 3 (0.5%) | 0.0%    | 0 (0.0%) | 0.0%    | 1 (0.1%)  | 3 (0.3%) |

* indicates that the SNP was observed with a minor allele frequency of 1% or greater in the given series. — indicates that the SNP was not observed in the given series.

SNP=single nucleotide polymorphism. MA=major allele. MAF=minor allele frequency.

doi: 10.1371/journal.pone.0075035.t003

evaluated using logistic regression models, separately for the familial Caucasian series, ISGS Caucasian series, combined Caucasian series, and ISGS African American series. Odds ratios (ORs) and 95% confidence intervals (CIs) were estimated. Models involving the familial Caucasian series and combined Caucasian series were adjusted for age and gender, with adjustment also made for series in the combined Caucasian series. Models for the ISGS Caucasian and African American series were adjusted for age, gender, CAD, diabetes, hypertension, current smoking, and atrial fibrillation (ISGS Caucasian series only). As no ISGS African American controls had atrial fibrillation, this characteristic was not adjusted for in that series. Associations of NOTCH3 variants with ischemic stroke subtypes (cardioembolic stroke, large vessel stroke, small vessel stroke) were also evaluated in all individual series except the ISGS African American series due to its small sample size. In the primary analysis we utilized additive models (effect of each additional minor allele), though in secondary analysis we also examined dominant models (presence vs. absence of the minor allele). For NOTCH3 variants with a minor allele frequency of less than 1%, we estimated the proportion of carriers in each series, separately for ischemic stroke patients and controls. We employed a single-step minP permutation correction in order to account for the number of statistical tests that were performed in our logistic regression analysis [16], separately for each series and separately for each ischemic stroke outcome (overall, cardioembolic, large-vessel, small-vessel). Following this multiple testing adjustment, p-values ≤0.0056 (familial Caucasian series), ≤0.0067 (ISGS Caucasian series), ≤0.0048 (combined Caucasian series), and ≤0.0061 (ISGS African American series) were considered as statistically significant. All statistical analyses were performed using R Statistical Software (version 2.14.0; R Foundation for Statistical Computing, Vienna, Austria).
Results

We identified 39 variants in our comprehensive sequencing of the NOTCH3 gene in the 269 familial ischemic stroke probands and 95 control subjects (Table 2). When examining the frequency of these variants utilizing both the familial Caucasian patient-control series and the ISGS Caucasian and African American patient-control series, 26 variants were observed with a minor allele frequency of less than 1% in any of the individual series; frequencies of these rare variants are detailed in Table 3 separately for stroke patients and controls in each series. Of note, in our stroke probands, we identified one novel variant in exon 4, which results in a histidine-to-arginine substitution p.H170R that is adjacent to known CADASIL mutants (p.R169C and p.G171C). This occurred in a 75-year-old Caucasian female with a TOAST subtype of ‘other determined etiology’. However when screened in controls this variant was observed at an equivalent frequency as in stroke patients in the combined Caucasian series (0.7% and 0.4% carriers, Table 3); p.H170R was not observed in the ISGS African American series.

One proband was observed to carry a known CADASIL causing mutation p.R558C (c. 1750 C>T). This patient was a 65-year-old man who presented for emergent medical attention with right arm weakness and mild dysarthria, which was caused by an acute infarct involving the posterior limb of the left internal capsule. The infarct occurred despite being prescribed cardizem, cardura, pravachol and aspirin. He had a history of one prior ischemic stroke 12 years earlier, sleep apnea, hyperlipidemia and hypertension, but not migraine headaches. MRI revealed a focal area of restricted diffusion corresponding to the presenting deficit along with bilateral small chronic infarcts and patchy leukoaraiosis (Figure 1). The affected sibling of the proband was also found to harbor the NOTCH3 p.R558C substitution.

A total of 19 variants were observed with a minor allele frequency of 1% or greater in any of the individual series (9 variants had a minor allele frequency ≥1% in all 4 series); an evaluation of association of these 19 common variants with risk of overall ischemic in each series is shown in Table 4 under an additive model. In the combined Caucasian series, the only common NOTCH3 variant that was significantly associated with ischemic stroke after correction for multiple testing was p.R1560P (rs78501403, OR: 0.50, 95% CI: 0.31-0.79, P=0.0022). This association was strongest in the familial Caucasian patient-control series (OR: 0.23, 95% CI: 0.10-0.55, P<0.001), whereas although a protective effect was observed in the ISGS Caucasian series, this did not approach significance (OR: 0.83, 95% CI: 0.41-1.66, P=0.60). Although not significant, noteworthy trends toward association with ischemic stroke to were observed for p.T101T (rs3815188) in the combined Caucasian series (OR: 1.22, 95% CI: 0.99-1.50, P=0.058), p.P2074L (rs114447350) in the ISGS African American series (OR: 2.29, 95% CI: 0.98-5.34, P=0.056), and p.P2271P (rs61731974) in the ISGS African American series (OR: 2.44, 95% CI: 0.91-6.54, P=0.077). Results of ischemic stroke association analysis were similar under a dominant model (Table S1).

Associations of NOTCH3 variants with cardioembolic, large-vessel, and small-vessel ischemic stroke in the combined...
Table 4. Single SNP associations with ischemic stroke under an additive model.

| SNP    | Amino Acid | MA MAF | OR (95% CI) | P-value | MA MAF | OR (95% CI) | P-value | MA MAF | OR (95% CI) | P-value | MA MAF | OR (95% CI) | P-value |
|--------|------------|--------|-------------|---------|--------|-------------|---------|--------|-------------|---------|--------|-------------|---------|
| rs3815188 | T101T     | A | 16.8% | 1.40 (1.07, 1.84) | 0.015 | 13.6% | 1.03 (0.74, 1.44) | 0.86 | 15.3% | 1.22 (0.99, 1.50) | 0.058 | 27.1% | 1.05 (0.70, 1.56) | 0.83 |
| rs1043994 | A202A     | T | 12.7% | 0.91 (0.67, 1.22) | 0.52 | 12.4% | 0.93 (0.67, 1.29) | 0.68 | 12.6% | 0.95 (0.77, 1.17) | 0.62 | 9.6% | 0.84 (0.47, 1.51) | 0.56 |
| rs61749020 | P380P     | G | 3.4% | 1.17 (0.62, 2.19) | 0.63 | 3.3% | 0.85 (0.57, 1.28) | 0.44 | 2.2% | 1.63 (0.45, 5.91) | 0.46 |
| rs11670799 | P496L    | T | 1.7% | 0.70 (0.45, 1.24) | 0.43 | 1.5% | 0.87 (0.47, 1.62) | 0.66 | + | + | + | + | + | + |
| rs35793356 | G594G     | A | + | + | + | + | + | + | + | + | + | + | + | + |
| rs35793356 | C846C     | G | + | + | + | + | + | + | + | + | + | + | + | + |
| rs1043996 | C846C     | G | + | + | + | + | + | + | + | + | + | + | + | + |
| rs1043997 | P914P     | T | 15.0% | 1.00 (1.17, 1.26) | 1.08 | 29.7% | 1.00 (0.92, 1.27) | 0.35 | 26.4% | 1.00 (0.57, 2.15) | 0.77 |
| rs35793356 | A1020P    | G | 2.2% | 1.33 (0.46, 3.79) | 0.60 | 1.7% | 0.88 (0.51, 1.51) | 0.64 | 28.5% | 1.12 (0.75, 1.67) | 0.59 |
| rs112197217 | H1133Q    | T | 1.1% | 0.88 (0.43, 1.82) | 0.74 | 1.6% | 0.99 (0.56, 1.74) | 0.97 | + | + | + | + | + | + |
| rs10408676 | V1183M    | T | 1.6% | 0.60 (0.25, 1.45) | 0.26 | 2.1% | 0.88 (0.43, 1.62) | 0.74 | 1.6% | 0.99 (0.56, 1.74) | 0.97 | + | + | + |
| rs1044006 | P1521P    | T | 9.9% | 0.81 (0.58, 1.15) | 0.24 | 5.9% | 0.83 (0.41, 1.66) | 0.60 | 3.3% | 0.50 (0.31, 0.79) | 0.002 | 4.4% | 1.35 (0.54, 3.37) | 0.52 |
| rs78501403 | R1560P    | G | 3.7% | 0.83 (0.41, 1.66) | 0.60 | 3.3% | 0.76 (0.42, 1.38) | 0.37 | 36.8% | 1.09 (0.75, 1.59) | 0.65 |
| rs16980398 | A1842A    | G | 2.1% | 0.87 (0.43, 1.74) | 0.74 | 1.6% | 0.99 (0.56, 1.74) | 0.97 | + | + | + | + | + | + |
| rs115582213 | V1952M    | T | 1.3% | 0.60 (0.22, 1.63) | 0.32 | 1.1% | 0.96 (0.34, 2.71) | 0.93 | 1.2% | 0.85 (0.44, 1.65) | 0.64 | + | + | + |
| rs11447350 | P2074L    | T | + | + | + | + | + | + | + | + | + | + | + | + |
| rs1044008 | A2146A    | T | 4.6% | 0.97 (0.63, 1.49) | 0.90 | 4.5% | 1.15 (0.63, 1.93) | 0.41 | + | + | + | + | + | + |
| rs1044009 | P2223V    | C | 23.7% | 0.97 (0.63, 1.54) | 0.90 | 4.5% | 1.15 (0.63, 1.93) | 0.41 | + | + | + | + | + | + |
| rs61731975 | S2251S    | A | + | + | + | + | + | + | + | + | + | + | + | + |
| rs61731974 | S2251S    | P | + | + | + | + | + | + | + | + | + | + | + | + |

1 The minor allele for rs1043996 was G in the Caucasian series' and A in the ISGS African American series. + indicates that the SNP was observed with a minor allele frequency of less than 1% or greater in the given series. --- indicates that the SNP was not observed in the given series. ORs and p-values result from logistic regression models adjusted for age and gender (Familial SWISS Caucasian series), age, gender, atrial fibrillation, coronary artery disease, diabetes, hypertension, and current smoking (ISGS Caucasian series), age, gender, and series (Combined Caucasian series), and age, gender, coronary artery disease, diabetes, hypertension, and current smoking (ISGS African American series). ORs correspond to an additional minor allele. SNP= single nucleotide polymorphism. MA= minor allele. MAF= minor allele frequency. OR= odds ratio. CI= confidence interval. ISGS= Ischemic Stroke Genetics Study.

Caucasian series under an additive model are displayed in Table 5. No variants were significantly associated with these ischemic stroke subtypes after multiple testing adjustment, although non-significant trends toward association were observed for p.T101T, which was associated with increased risk of small-vessel stroke (OR: 1.56, 95% CI: 1.12-2.18, P=0.008), and p.P380P (rs61749020), which was associated with a decreased risk of large-vessel stroke (OR: 0.35, 95% CI: 0.12-0.98, P=0.047). The aforementioned association with ischemic stroke for p.R1560P was relatively consistent in
magnitudes across ischemic stroke subtypes, though strongest for small-vessel stroke (OR: 0.36, P=0.053), followed by cardioembolic stroke (OR: 0.48, P=0.13) and large-vessel stroke (OR: 0.67, P=0.30). Results were similar under a dominant model (data not shown). Associations of NOTCH3 variants with stroke subtypes in the individual familial Caucasian and ISGS Caucasian series are displayed in Tables S2 and S3, while genotype frequencies for each NOTCH3 variant are shown in Tables S4-S7 for each series.

Discussion

Rare mutations within the NOTCH3 gene resulting in the gain or loss of a cysteine residue produce the CADASIL phenotype. We set out to examine whether CADASIL-linked mutations can also produce a clinical phenotype that is more reminiscent of typical ischemic stroke. In addition, we examined if other coding variants in NOTCH3, common or rare variation, affect the individual susceptibility to ischemic stroke.

One of the variants identified is known pathogenic CADASIL substitution (p.R558C) and was identified in a proband with a history of small vessel stroke. In addition to p.R558C substitution, we observed a number of rare variants within the NOTCH3 gene, 15 of which are non-synonymous. When evaluating associations with ischemic stroke for common variants, we observed an association for p.R1560P in the combined Caucasian series that withstood correction for multiple testing, where presence of the minor allele was associated with a lower risk of ischemic stroke with an odds ratio of 0.50. This protective effect for p.R1560P was also observed when considering ischemic stroke subtypes (although not statistically significant in these lower-powered analyses), and was strongest for small-vessel ischemic stroke. Employing the Polyphen (Polymorphism phenotyping) freeware, which predicts the effect of an amino acid substitution, suggests that the p.R1560P may possibly damage the structure and function of the NOTCH3 protein and could support a functional effect by this substitution [17].

A recent study by Schmidt and colleagues examined the presence of NOTCH3 variants in an elderly series and assessed whether they play a role in age-related small vessel disease [18]. They observed a risk association of a number of common variants and the presence of white matter lesions; however, the association was only present in hypertensive individuals, they did not observe the p.R1560P variant, suggesting that the p.R1560P variant may display different disease associations depending on population. Indeed, the association was only present in hypertensive individuals, they did not observe the p.R1560P variant, suggesting that the p.R1560P variant may display different disease associations depending on population.

Table 5. Single SNP associations with ischemic stroke subtypes in the combined Caucasian series under an additive model.

| SNP       | Amino Acid | MA | MAF | OR (95% CI) | P-value | OR (95% CI) | P-value | OR (95% CI) | P-value |
|-----------|------------|----|-----|------------|---------|------------|---------|------------|---------|
| rs3815188 | T101T      | A  | 15.3% | 0.96 (0.65, 1.43) | 0.85 | 0.96 (0.66, 1.39) | 0.83 | 1.56 (1.12, 2.18) | 0.0082 |
| rs1043994 | A202A      | T  | 12.6% | 1.28 (0.91, 1.61) | 0.16 | 1.05 (0.74, 1.49) | 0.78 | 0.82 (0.66, 1.20) | 0.31 |
| rs61749020| P380P      | G  | 3.3% | 0.60 (0.25, 1.49) | 0.27 | 0.35 (0.12, 0.98) | 0.047 | 1.16 (0.59, 2.28) | 0.67 |
| rs11670799| P436L      | T  | 1.5% | 0.56 (0.12, 2.59) | 0.46 | 0.67 (0.19, 2.29) | 0.52 | 0.87 (0.29, 2.56) | 0.79 |
| rs1043996 | C846C      | G  | 29.7% | 1.11 (0.84, 1.47) | 0.48 | 1.02 (0.78, 1.34) | 0.86 | 1.15 (0.88, 1.50) | 0.31 |
| rs1043997 | P914P      | T  | 14.2% | 1.21 (0.86, 1.70) | 0.28 | 1.08 (0.77, 1.51) | 0.65 | 0.79 (0.54, 1.14) | 0.20 |
| rs35769976| A1020P     | G  | 1.7% | 0.53 (0.13, 2.23) | 0.39 | 0.61 (0.20, 1.90) | 0.40 | 1.07 (0.47, 2.43) | 0.67 |
| rs112197217| H1133Q    | T  | 1.6% | 1.07 (0.45, 2.52) | 0.86 | 1.00 (0.38, 2.61) | 1.00 | 1.22 (0.47, 3.17) | 0.68 |
| rs10408076| V1183M     | T  | 1.1% | 0.41 (0.06, 3.07) | 0.39 | 0.30 (0.04, 2.17) | 0.24 | 1.02 (0.37, 2.83) | 0.97 |
| rs1044006 | P1521P     | T  | 9.7% | 1.25 (0.84, 1.86) | 0.26 | 1.09 (0.74, 1.62) | 0.66 | 0.81 (0.52, 1.25) | 0.34 |
| rs78501403| R1560P     | G  | 3.3% | 0.48 (0.18, 1.24) | 0.13 | 0.67 (0.31, 1.43) | 0.30 | 0.36 (0.13, 1.01) | 0.053 |
| rs19880398| A1842A     | G  | 1.4% | 0.35 (0.05, 2.53) | 0.30 | 0.74 (0.25, 2.19) | 0.59 | 1.22 (0.55, 2.70) | 0.62 |
| rs115582213| V1952M    | T  | 1.2% | 1.75 (0.66, 4.65) | 0.26 | 1.21 (0.44, 3.27) | 0.71 | 0.49 (0.11, 2.09) | 0.33 |
| rs1044008 | A2146A     | T  | 4.5% | 1.11 (0.63, 1.94) | 0.72 | 0.67 (0.33, 1.34) | 0.25 | 1.28 (0.75, 2.17) | 0.37 |
| rs1044009 | A2223V     | C  | 22.9% | 1.22 (0.90, 1.65) | 0.21 | 1.08 (0.80, 1.45) | 0.62 | 1.25 (0.93, 1.66) | 0.14 |

ORs and P-values result from logistic regression models adjusted for age, gender, and series. ORs correspond to an additional minor allele. SNP=single nucleotide polymorphism. MA=minor allele. MAF=minor allele frequency. OR=odds ratio. CI=confidence interval.

doi: 10.1371/journal.pone.0075035.b005
as the reference for imputation [http://www.1000genomes.org]. Therefore further specific genotyping of this variant may be warranted.

There are several limitations of our study that should be acknowledged. Chief among these is the relatively small sample size. As a result, power to detect associations of NOTCH3 variants with ischemic stroke and ischemic stroke subtypes is low, and the possibility of Type II error (i.e. a false-negative association) is important to acknowledge, especially after correction for multiple testing. This is particularly true in the African American series and in examination of associations of NOTCH3 variants with ischemic stroke subtypes. Related to this, assessment of rare variants is challenging in our relatively small study. Also, though the finding regarding p.R1560P achieved statistical significance after multiple testing adjustment, given the stronger association in the Familial Caucasian series than in the ISGS Caucasian series, it will be important to validate this finding as well as other results of our study involving both common and rare variants in larger series.'

The NOTCH pathway is a fundamental signaling mechanism determining cell fate choices [19]. NOTCH 1-4 are cell surface receptors, which interact with membrane-bound ligands transducing signals between neighboring cells. The NOTCH3 receptor has been reported to promote vascular smooth muscle cell survival. To date the confirmed pathogenic CADASIL mutations are located in the epidermal growth factor (EGF)-like repeat domains at the extracellular N-domain of the receptor. Missense and splice-site mutations and in-frame deletions have been observed in patients. Mutations appear to affect highly conserved cysteine residues. Within each wild-type EGF-like repeat there are six cysteine residues, while in CADASIL mutation patients there is a loss or gain of a cysteine residue. This uneven number of cysteine residues has been hypothesized to effect differential protein interactions and the possible multimerization of mutant NOTCH3.

The association of NOTCH3 p.R1560P suggests that disruption of the normal NOTCH3 receptor function could modulate the risk of ischemic stroke. Additional studies in large patient-control series and other ethnicities are required to fully elucidate the role of NOTCH3 variation in disease and the underlying pathomechanism that results in ischemia.

Supporting Information

Figure S1. Linkage disequilibrium (LD) plots for common NOTCH3 variants.

(PPTX)

Table S1. Single SNP associations with ischemic stroke under a dominant model.

(DOCX)

Table S2. Single SNP associations with ischemic stroke subtypes in the familial Caucasian series under an additive model.

(DOCX)

Table S3. Single SNP associations with ischemic stroke subtypes in the ISGS Caucasian series under an additive model.

(DOCX)

Table S4. Genotype frequencies in the Familial Caucasian series.

(DOCX)

Table S5. Genotype frequencies in the ISGS Caucasian series.

(DOCX)

Table S6. Genotype frequencies in the combined Caucasian series.

(DOCX)

Table S7. Genotype frequencies in the ISGS African American series.

(DOCX)

Acknowledgements

We would like to thank all those who have contributed to our research, particularly the patients and families who donated DNA samples for this work. Samples from the Human Genetics Resource Center DNA and Cell Line Repository (ccr.coriell.org) were used. For further details on our research in cerebrovascular disease please visit our web-site; http://mayoresearch.mayo.edu/mayo/research/ross_lab/

Author Contributions

Conceived and designed the experiments: OAR AISO MGH RG JFM. Performed the experiments: AISO CV SR EK. Analyzed the data: OAR AISO MGH CV DJS EK MAN. Contributed reagents/materials/analysis tools: OAR SSR MAN AS RG ZKW TGB RDB BBW JFM. Wrote the manuscript: OAR MGH. Drafting the article or revising it critically for important intellectual content: OAR AISO MGH CV SR SSR MAN AS RG ZKW TGB RDB BBW JFM. Final approval of the version to be published: OAR AISO MGH CV DJS SR SSR MAN AS RG ZKW TGB RDB BBW JFM.

References
NOTCH3 and Ischemic Stroke

1. Meschia JF, Worrall BB, Rich SS (2011) Genetic susceptibility to ischemic stroke. Nat. Rev Neurol 7: 369-378. doi:10.1038/nrneurol.2011.80.
2. Ross OA, Worrall BB, Meschia JF (2007) Advancing stroke therapeutics through genetic understanding. Curr Drug Targets 8: 850-859. doi:10.2174/138945007781077355. PubMed: 17630939.
3. Jouvet A, Corpechot C, Ducros A, Vahedi K, Chabriat H et al. (1996) Notch3 mutations in CADASIL, a hereditary adult-onset condition causing stroke and dementia. Nature 383: 707-710. doi: 10.1038/383707a0. PubMed: 8878478.
4. Federico A, Bianchi S, Dotti MT (2005) The spectrum of mutations for CADASIL diagnosis. Neuril Sci 26: 117-124. doi:10.1007/s10072-005-0444-3. PubMed: 15995628.
5. Dichgans M (2003) Ch.6 Monogenic causes of ischaemic stroke. In: H Markus. Stroke Genetics. Publ. Oxford Press. pp.165-195.
6. Guidetti D, Casali B, Mazei RL, Dotti MT (2006) Cerebral autosomal dominant arteriopathy with subcortical infarcts and leukoencephalopathy. Clin Exp Hypertens 28: 271-277. doi: 10.1080/10641960600549223. PubMed: 16833034.
7. Kalimo H, Ruchoux MM, Villanen M, Kalaria RN (2002) CADASIL: a common form of hereditary arteriopathy causing brain infarcts and dementia. Brain Pathol 12: 371-384. PubMed: 12146805.
8. Pescini F, Bianchi S, Salvadori E, Poggesi A, Dotti MT et al. (2008) A pathogenic mutation on exon 21 of the NOTCH3 gene causing CADASIL in an octogenarian paucisymptomatic patient. J Neurol Sci 267: 170-173. doi:10.1016/j.jns.2007.10.017. PubMed: 18022198.
9. Vikelis M, Papatriantafyllou J, Karageorgiou CE (2007) A novel CADASIL-causing mutation in a stroke patient. Swiss Med Wkly 137: 323-325. PubMed: 17628811.
10. Fouillard C, Chabriat H, Riant F, Mine M, Arnoud M et al. (2008) Activating NOTCH3 mutation in a patient with small-vessel-disease of the brain. Hum Mutat 29: 452. doi:10.1002/humu.9526. PubMed: 18273901.
11. Arboleda-Velasquez JF, Zhou Z, Shin HK, Louvi A, Kim HH et al. (2008) Linking Notch signaling to ischemic stroke. Proc Natl Acad Sci U S A 105: 4856-4861. doi:10.1073/pnas.0709867105. PubMed: 18347334.
12. (1988) The World Health Organization MONICA Project (monitoring trends and determinants in cardiovascular disease): a major international collaboration. WHO MONICA Project Principal Investigators. J Clin Epidemiol 41: 105-114. doi: 10.1016/0895-4356(88)90084-4. PubMed: 3335877.
13. Adams HP Jr., Bendixen BH, Kappelle LJ, Biller J, Love BB et al. (1993) Classification of subtype of acute ischemic stroke. Definitions for use in a multicenter clinical trial. TOAST. Trial of Org 10172 in Acute Stroke Treatment. Stroke 24: 35-41.
14. Guerreiro RJ, Lohmann E, Kinsella E, Bras JM, Luu N et al. (2011) Exome sequencing reveals an unexpected genetic cause of disease: NOTCH3 mutation in a Turkish family with Alzheimer’s disease. Neurobiol Aging.
15. Barrett JC (2009) Haploview: Visualization and analysis of SNP genotype data. Cold Spring Harb Protoc 2009: pdb ip71.
16. Dudor D, van der Laan MJ, Pollard KS (2004) Multiple testing. Part I. Single-step procedures for control of general type I error rates. Stat Appl Genet Mol Biol 3: Article13
17. Ramensky V, Bork P, Sunyaev S (2002) Human non-synonymous SNPs: server and survey. Nucleic Acids Res 30: 3894-3900. doi: 10.1093/nar/gkf493. PubMed: 12202775.
18. Schmidt H, Zegni G, Wiltgen M, Freudenberger P, Petrovic K et al. (2011) Genetic variants of the NOTCH3 gene in the elderly and magnetic resonance imaging correlates of age-related cerebral small vessel disease. Brain 134: 3384-3397. doi:10.1093/brain/awr225. PubMed: 22006983.
19. High FA, Epstein JA (2008) The multifaceted role of Notch in cardiac development and disease. Nat Rev Genet 9: 49-51. doi:10.1038/nrg2279. PubMed: 18071321.